{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:21:04Z","timestamp":1779146464738,"version":"3.51.4"},"reference-count":26,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,11,14]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Etoposide addition\/chemo-intensification has little role in first-line treatment of PTCL in Asian populations, regardless of subtype or age. Upfront hematopoietic stem-cell transplantation as consolidation seems like a legitimate choice in patients with PTCL.<\/jats:p>","DOI":"10.1182\/bloodadvances.2017010819","type":"journal-article","created":{"date-parts":[[2017,10,28]],"date-time":"2017-10-28T00:40:19Z","timestamp":1509151219000},"page":"2138-2146","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":31,"title":["Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma"],"prefix":"10.1182","volume":"1","author":[{"given":"Young Ae","family":"Kim","sequence":"first","affiliation":[{"name":"Cancer Policy Branch, National Cancer Control Institute, National Cancer Center, Goyang-si, Korea;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ja Min","family":"Byun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Boramae Hospital, Seoul, Korea;"},{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keeho","family":"Park","sequence":"additional","affiliation":[{"name":"Cancer Policy Branch, National Cancer Control Institute, National Cancer Center, Goyang-si, Korea;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gi Hwan","family":"Bae","sequence":"additional","affiliation":[{"name":"Cancer Policy Branch, National Cancer Control Institute, National Cancer Center, Goyang-si, Korea;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dukhyoung","family":"Lee","sequence":"additional","affiliation":[{"name":"National Cancer Control Institute, National Cancer Center, Goyang-si, Korea; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Sook","family":"Kim","sequence":"additional","affiliation":[{"name":"Health Insurance Review Agency, Wonju-si, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2017,10,27]]},"reference":[{"issue":"25","key":"2019111617152250000_B1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111617152250000_B2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2005-03-1306","article-title":"T-cell non-Hodgkin lymphoma","volume":"107","author":"Rizvi","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2019111617152250000_B3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/oxfordjournals.annonc.a057673","article-title":"Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d\u2019Etude des Lymphomes Agressives)","volume":"1","author":"Coiffier","year":"1990","journal-title":"Ann Oncol"},{"issue":"2","key":"2019111617152250000_B4","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cncr.27733","article-title":"Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350","volume":"119","author":"Mahadevan","year":"2013","journal-title":"Cancer"},{"issue":"10","key":"2019111617152250000_B5","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"1 suppl","key":"2019111617152250000_B6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/1097-0142(19910101)67:1+<271::AID-CNCR2820671311>3.0.CO;2-L","article-title":"The evolving role of etoposide in the management of lymphomas and Hodgkin\u2019s disease","volume":"67","author":"O\u2019Reilly","year":"1991","journal-title":"Cancer"},{"issue":"12","key":"2019111617152250000_B7","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1093\/annonc\/mdp211","article-title":"High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)","volume":"20","author":"Nickelsen","year":"2009","journal-title":"Ann Oncol"},{"issue":"1","key":"2019111617152250000_B8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1748-717X-5-80","article-title":"Normalization of prostate specific antigen in patients treated with intensity modulated radiotherapy for clinically localized prostate cancer","volume":"5","author":"Schmitz","year":"2010","journal-title":"Radiat Oncol"},{"issue":"3","key":"2019111617152250000_B9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s12032-008-9046-2","article-title":"Results of a phase III clinical trial: CHOP versus CMED in peripheral T-cell lymphoma unspecified","volume":"25","author":"Avil\u00e9s","year":"2008","journal-title":"Med Oncol"},{"issue":"3","key":"2019111617152250000_B10","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"issue":"3","key":"2019111617152250000_B11","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"issue":"18","key":"2019111617152250000_B12","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"2019111617152250000_B13","unstructured":"National Comprehensive Cancer Network. T-cell lymphoma guidelines. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/t-cell.pdf. Accessed 3 May 2017."},{"issue":"15","key":"2019111617152250000_B14","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111617152250000_B15","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2005-04-1570","article-title":"Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma","volume":"107","author":"Glass","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2019111617152250000_B16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.4143\/crt.2005.37.6.325","article-title":"Nationwide cancer incidence in Korea, 1999\u223c2001; first result using the national cancer incidence database","volume":"37","author":"Shin","year":"2005","journal-title":"Cancer Res Treat"},{"key":"2019111617152250000_B17","volume-title":"International Classification of Diseases for Oncology","author":"Fritz","year":"2000","edition":"3rd ed."},{"key":"2019111617152250000_B18","volume-title":"International Statistical Classification of Diseases and Related Health Problems","author":"World Health Organization","year":"1994","edition":"10th ed."},{"issue":"2","key":"2019111617152250000_B19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/19371911003648275","article-title":"Special issue on the national health care system of South Korea","volume":"25","author":"Kim","year":"2010","journal-title":"Soc Work Public Health"},{"issue":"2","key":"2019111617152250000_B20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/19371910903070333","article-title":"Introduction: health of the health care system in Korea","volume":"25","author":"Kim","year":"2010","journal-title":"Soc Work Public Health"},{"issue":"5","key":"2019111617152250000_B21","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"4","key":"2019111617152250000_B22","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111617152250000_B23","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","article-title":"How I treat the peripheral T-cell lymphomas","volume":"123","author":"Moskowitz","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2019111617152250000_B24","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/ajh.21824","article-title":"Distribution of lymphoid neoplasms in the Republic of Korea: analysis of 5318 cases according to the World Health Organization classification","volume":"85","author":"Yoon","year":"2010","journal-title":"Am J Hematol"},{"issue":"12","key":"2019111617152250000_B25","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/bmt.2008.332","article-title":"Hematopoietic SCT for peripheral T-cell lymphoma","volume":"42","author":"Guti\u00e9rrez","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"2019111617152250000_B26","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","article-title":"Autologous transplantation as consolidation for aggressive non-Hodgkin\u2019s lymphoma","volume":"369","author":"Stiff","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/24\/2138\/879011\/advances010819.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/24\/2138\/879011\/advances010819.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T22:15:36Z","timestamp":1573942536000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/1\/24\/2138\/16211\/Redefining-the-role-of-etoposide-in-firstline"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,27]]},"references-count":26,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2017,11,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2017010819","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,27]]}}}